The effect of Cannabidiol (CBD) on paranoid cognitions in humans

Not Applicable

Completed

• Conditions: Paranoid cognitions; Mental and Behavioural Disorders

• Registration Number: ISRCTN11082858
• Lead Sponsor: King's College London (UK)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2013-08-16
• Study Completion: 2015-08-22
• Last Update Posted: 14 September 2020

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

1. Aged 18-50 years
2. English as first language
3. Patient at OASIS service

Exclusion Criteria

1. Subjects who have been diagnosed with a major mental or physical illness (epilepsy, schizophrenia, bipolar disorder)
2. Subjects must not have had previous treatment with antipsychotic or mood stabilising drugs
3. Pregnancy
4. Drug/alcohol dependence

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<br> 1. Autonomic arousal using pulse and respiratory rates and saliva swabs to measure cortisol<br> 2. Paranoid thinking using the State-Social Paranoid Scale and the Cape-(state version)<br> 3. Affective processing using the Beck Anxiety Inventory, the Bond and Lader Visual Analogue Scale and the Negative-Self-Statement-Scale<br>

Secondary Outcome Measures

Name	Time	Method
Cognitive functioning using the Letter-Number-Span to measure working memory, and the Hopkins-Verbal-Learning-Task-Revised